PE-22-28 vs SS-31 (Elamipretide)

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

PE-22-28

PE-22-28 is a synthetic peptide fragment derived from research on the SAMP8 mouse model of accelerated aging. It has shown potential for enhancing memory and reducing cognitive decline.

Full details →

SS-31 (Elamipretide)

SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.

Full details →

Side-by-Side Comparison

Aspect	PE-22-28	SS-31 (Elamipretide)
Dose Range	500 mcg–2 mg	20 mg–40 mg
Frequency	1x daily	1x daily
Cycle Length	1–2 weeks	4–12 weeks
Route	subcutaneous	subcutaneous
Mechanism	Derived from the protein that is deficient in SAMP8 mice. May work by inhibiting protein phosphatase 2A methylesterase, thereby affecting memory-related signaling pathways.	Concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency.
Typical Dosage	Research protocols vary. Intranasal dosing has been studied at various concentrations. Optimal human dosing not established.	Clinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily.
Administration	Intranasal administration preferred for CNS delivery. Research compound with limited human use data.	Can be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions.
Side Effects	Very limited human data. Primarily studied in animal models for safety and efficacy.	Generally well-tolerated. Clinical trials reported injection site reactions and occasional headache.
Best For	Cognitive Performance Anti-Aging & Longevity	Recovery & Healing Anti-Aging & Longevity